Black Diamond Therapeutics Reports Positive Phase 2 Silevertinib Results in NSCLC, Plans FDA Meeting
BDTX sits 65% above its 52-week low of $1.93 on elevated volume (5.2× avg).
Summary
Black Diamond Therapeutics announced positive Phase 2 results for its lead drug candidate, silevertinib, in frontline NSCLC patients with EGFR non-classical mutations, demonstrating strong efficacy and a favorable safety profile.
Key Events · Product Development and Regulatory · BDTX
-
Positive Phase 2 Silevertinib Results
Black Diamond Therapeutics announced positive Phase 2 results for silevertinib in frontline non-small cell lung cancer (NSCLC) patients with EGFR non-classical mutations.
-
Strong Efficacy and Durability
The trial showed a preliminary median Progression-free Survival (mPFS) of 15.2 months and a median duration of response (DOR) that had not been reached, with 53% of patients remaining on therapy.
-
Robust CNS Activity
Silevertinib demonstrated strong central nervous system (CNS) activity with an 86% CNS Objective Response Rate (ORR) and no patients developing de novo brain metastases.
-
Favorable Safety Profile
No new safety signals were observed, and the rate of treatment-related adverse events (TRAEs) > Grade 3 was reduced to 28% following dose reduction, with patients maintaining responses.
Analysis · BDTX · Life Sciences
The positive Phase 2 results for silevertinib are critical for Black Diamond Therapeutics, a clinical-stage oncology company. The strong efficacy data, including a preliminary median Progression-free Survival (mPFS) of 15.2 months and robust CNS activity, significantly de-risk the lead asset. This positive clinical update provides a strong counterpoint to the company's recently reduced cash runway guidance, potentially improving investor confidence and future financing prospects as the company prepares for pivotal development discussions with the FDA.
At the time of this filing, BDTX was trading at $3.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $203.4M. The 52-week trading range was $1.93 to $4.94. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.